Table_2_Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients.xlsx

BackgroundDiffuse large B-cell lymphoma (DLBCL) is a kind of highly heterogeneous non-Hodgkin lymphoma, both in clinical and genetic terms. DLBCL is admittedly categorized into six subtypes by genetics, which contain MCD, BN2, EZB, N1, ST2, and A53. Dyslipidemia is relevant to a multitude of solid tumors and has recently been reported to be associated with hematologic malignancies. We aim to present a retrospective study investigating dyslipidemia in DLBCL based on the molecular subtypes.ResultsThis study concluded that 259 patients with newly diagnosed DLBCL and their biopsy specimens were available for molecular typing. Results show that the incidence of dyslipidemia (87.0%, p

背景：弥漫性大B细胞淋巴瘤（DLBCL）在临床和遗传学层面均表现为一种高度异质性的非霍奇金淋巴瘤。DLBCL在遗传学上无疑可分为六种亚型，包括MCD、BN2、EZH2、N1、ST2和A53。血脂异常与多种实体瘤密切相关，并且最近有报道指出其与血液系统恶性肿瘤存在关联。本研究旨在基于分子亚型对DLBCL中的血脂异常进行回顾性研究。结果：本研究共纳入259例新诊断的DLBCL患者及其活检标本进行分子分型。结果显示，血脂异常的发病率高达87.0%（p值未给出）。